

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249

Provisional Stakeholder List

| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| Company Janssen-Cilag (daratumumab, bortezomib) Patient/carer groups African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency for Equality Blood Cancer UK Cancer Black Care Cancer52 Helen Rollason Cancer Charity Independent Cancer Patients Voice Kevin Karawa Leukaemia Trust Leukaemia Cancer Society Leukaemia Care Leukaemia UK Macmillan Cancer Support Maggie's Centres Marie Curie | General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government NHS Wales Joint Commissioning Committee |
| Myeloma UK South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care Healthcare professional groups Association of Cancer Physicians British Blood Transfusion Society British Committee for Standards in Haematology British Geriatrics Society British Institute of Radiology | Possible comparator companies Advanz Pharma (lenalidomide) Amarox (lenalidomide) Baxter Healthcare (cyclophosphamide) Biocon Pharma (lenalidomide) Bristol Myers Squibb (lenalidomide, thalidomide) Grindeks Kalceks UK (lenalidomide) Mylan (lenalidomide) Ranbaxy UK (lenalidomide) Sandoz (cyclophosphamide, |

Provisional stakeholder list for evaluation of daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249 Issue date: March 2025



| Consultees | Commentators (no right to submit or appeal) |
|---|---|
| British Oncology Pharmacy Association British Psychosocial Oncology Society British Society for Haematology British Society of Interventional Radiology British Transplantation Society Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Myeloma Society UK Oncology Nursing Society Others Department of Health and Social Care NHS England | lenalidomide) Teva UK (lenalidomide) Thornton & Ross (lenalidomide) Zentiva (thalidomide) Relevant research groups Cochrane Haematological Malignancies Group Genomics England Institute of Cancer Research Leukaemia Busters MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for evaluation of daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249 Issue date: March 2025



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.